Refine your search

Search Results within category "Infectious Diseases & Immune System"

Search all categories

Suggestions within category "Infectious Diseases & Immune System"


Study matches: 9

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.


Procalcitonin Antibiotic Consensus Trial

The study objective is to target emergency department (ED) patients with clinically diagnosed lower respiratory tract infection (LRTI) and test the effects of implementation of a procalcitonin antibiotic guideline for LRTI.
Nancy Campbell RN at ncampbell1@pennstatehealth.psu.edu or 531-1707 ext. 3
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Lower respiratory lung infection < 28 days
Exclusion Criteria:
no antibiotic use for 72 hours before enrollment
no other infections
no cancer
no dialysis
no major surgery in past 7 days
Show full eligibility criteria
NCT02130986
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of CC-220 in Subjects with Active Systemic Lupus Erythematosus

This study is for patients with SLE (systemic lupus erythematosus) to determine the effectiveness and safety of drug CC-220 on improving SLE and to see how well the body tolerates the medication.
Jamie Carter at jcarter3@pennstatehealth.psu.edu or 717-531-0003
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of Systemic Lupus Erythematosus
Exclusion Criteria:
Diagnosis of Fibromyalgia
Active or history of recurrent bacterial, viral or fungal infections
History of latent or active tuberculosis
History of blood clots in the past year
Show full eligibility criteria
NCT03161483
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients with Stable, Quiescent Systemic Lupus Erythematosus (SLE)

This study is for patients diagnosed with systemic lupus erythematosus (SLE) who are taking MMF now and have been taking MMF for 1-2 years and your disease is not active. The purpose of this research study is to find out if patients who have been on MMF for 1 to 2 years and whose disease is quiet can safely stop their MMF medication. This could help standardize treatment for lupus patients in the long-run. Doctors know that continuing MMF for long periods of time can have side effects and they know that stopping MMF will put patients at a higher risk for flare; we are trying to find out how big this risk is and if it is better to stop or continue taking MMF.
Jamie Carter at jcarter3@pennstatehealth.psu.edu
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of Lupus
Currently taking Mycophenolate
Taking Hydroxychloroquine
Exclusion Criteria:
Taking prednisone greater than 25mg per day
Show full eligibility criteria
NCT01946880
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Microbiome And Procalcitonin Long term outcomes Epidemiology

An ancillary study to ProACT (IRB# 747 ) to determine the impact of a procalcitonin-antibiotic strategy on the microbiome changes that occur during a time of infection.
Nancy Campbell RN at ncampbell1@pennstatehealth.psu.edu or 717-531-1707 ext. 3
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Lower respiratory lung infection < 28 days
older than 18 yrs
Exclusion Criteria:
antibiotics within the last 72 hours
pregnant
metastatic cancer
severe immunosuppression
Show full eligibility criteria
N/A
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Registry of Patients with Primary Immunodeficiency Disorders

The United States Immunodeficiency Network (USIDNET) Consortium is a group of investigators funded by the National Institutes of Health (NIH) working in association with the Immune Deficiency Foundation (IDF) to conduct a study in which a patient Registry is being developed. The Immune Deficiency Foundation is the national patient organization dedicated to improving the diagnosis, treatment and quality of life of persons with primary immunodeficiency diseases through advocacy, education, and research. The IDF provides administrative support for USIDNET and developed the initial Registry of patients with Primary Immunodeficiency that has grown to become the current Registry.
D. Adriana Andreae, MD at dandreae@pennstatehealth.psu.edu
All
All
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Must have a known or suspected primary immune deficiency disease, or be a genetic carrier of such a defect
Exclusion Criteria:
Individuals with immunodeficiency associated with HIV infection, chemotherapy or other immunosuppressive therapies
Show full eligibility criteria
N/A
  Email this study information to me
  Contact the study team

A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects with Hereditary Angioedema

This study is for patients diagnosed with Type 1 or Type 2 Hereditary Angioedema (HAE) and have suffered HAE attacks (episodes of swelling), and are either not using HAE medications to prevent HAE attacks or for medical or personal choice reasons have decided to discontinue using these medications. This research is being done to compare the effects of two different doses of BCX7353 compared to placebo. Placebo-containing capsules look exactly like BCX7353 capsules, but do not contain BCX7353 or any other drug. The Sponsor will test two different doses of BCX7353 to see if BCX7353 is able to prevent or reduce the number of swelling episodes or attacks in people with HAE when taken every day by mouth, compared to placebo. This research study will also assess the safety of the new drug BCX7353.
Terri Smith at tjs97@psu.edu or 717-531-4513
All
All
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Adults & Children 12 years or older
Diagnoses with HAE Type 1 or Type 2
2 or more HAE attacks per month
Exclusion Criteria:
Pregnant females or planning on becoming pregnant or nursing
Anticipated use of short-term prophylaxis for pre-planned procedure or surgery
Chest pain, heart attack, passing out or significant heart beat abnormality
Pacemaker or defibrillator implanted
Family history of sudden cardiac death not related to HAE
Show full eligibility criteria
NCT03485911
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

VIOLET: Vitamin D to Improve Outcomes by Leveraging Early Treatment

To assess the efficacy and safety of early administration of vitamin D3 (cholecalciferol) in reducing mortality and morbidity for vitamin D deficient patients at high risk for Acute Respiratory Distress Syndrome (ARDS) and mortality.
Nancy Campbell RN at ncampbell1@pennstatehealth.psu.edu or 717-531-1707 ext. 3
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Admission to ICU with acute risk factors for Acute Respiratory Distress Syndrome (ARDS): Pneumonia, Aspiration, smoke inhalation, lung contusion, hypoxemia, intubation
shock
sepsis
pancreatitis
Vit. D deficiency
Exclusion Criteria:
unable to take Vit D by mouth
blood Calcium levels > 10.2
known kidney stone in past 1 year
Do Not Rescusitate orders (DNR)
prisoner
Show full eligibility criteria
NCT03096314
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A MULTICENTER OPEN-LABEL STUDY OF ETANERCEPT WITHDRAWAL AND RETREATMENT IN SUBJECTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WHO ACHIEVED ADEQUATE 24 WEEK RESPONSE

To estimate the proportion of subjects who flare within 40 weeks following withdrawal of ETN in subjects who have achieved ASDAS CRP less than 1.3 (inactive disease).
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Back Pain
Symptoms longer than 3 months less than 5 years
On a stable NSAID
ages 18-50
Exclusion Criteria:
Radiographic Sacroilitis
Previous treatment with a TNF-a Biologic inhibitor
Show full eligibility criteria
NCT02509026
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Cognitive abilities and markers of biobehavioral health: Evaluation of potential bi-directional associations

This study will examine how different ways of thinking and feeling emotions may be related to one's physiology. Participants will complete up to four lab visits (one visit is optional) within approximately three to four months where they will asked to indicate how they experience emotions and how they relate to other individuals in addition to completing brain games (e.g., puzzles, memory tasks). They will also complete a blood draw at each visit and provide saliva samples at one visit. Very little blood will be taken during visits (57 ml; a typical blood donation is approximately 475 ml). Participants will wear a non-invasive strap that measures their heart rate around their upper abdomen (except when sleeping or showering) and complete very brief questionnaires about their mood up to five times daily for two weeks on a cell phone provided to them. Participants can earn up to $300 for completing all study procedures.
Jasmin Guevara at jeg90@psu.edu or 814-865-6598
All
18 year(s) or older
This study is also accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Age 45 to 70
Able to attend clinic visits
Exclusion Criteria:
Pregnant or breastfeeding
Currently working evening shift
Us of non-steroidal anti-inflammatory drugs (NSAIDs)
Show full eligibility criteria
N/A
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA